Ann: Race AGM presentations and strategic update, page-29

I think there's a strong/massive opportunity for Bisantrene to be used in combination with the with the PD-1 inhibitors (due to treatment resistance) - Bisantrene could stop the treatment resistance of PD-1 inhibitors.

The kind of thing that will get big pharma very, very interested.

1420 studies for Keytruda
https://clinicaltrials.gov/ct2/resu...uda&cntry=&state=&city=&dist=

1286 studies for OPDIVO
https://clinicaltrials.gov/ct2/resu...IVO&cntry=&state=&city=&dist=

732 studies for YERVOY
https://clinicaltrials.gov/ct2/resu...VOY&cntry=&state=&city=&dist=








(colour-highlighted group above highlighted below - massive market - noting cancer resistance to PD-1 inhibitors)